PURPOSE: To determine differences in prognosis between primary progressive @entity978 ( @entity978 ) and aggressive @entity1893 ( @entity1893 ), we retrospectively analyzed @entity1 with @entity706 who were treated with different salvage chemotherapy regimens including high-dose chemotherapy (HDCT) followed by autologous stem-cell support (ASCT). @entity1 AND METHODS: One hundred thirty-one @entity1 with primary @entity706 ( @entity978 , n = 67; @entity1893 , n = 64) were enrolled. @entity74 was defined as disease progression during first-line chemotherapy or only transient response (complete or partial response lasting </= 90 days) after induction treatment. @entity1 60 years or younger with @entity706 were eligible to receive HDCT with ASCT. RESULTS: The overall response rate after salvage chemotherapy for @entity1 with primary progressive @entity978 and @entity1893 was 33% and 15%, respectively. Twenty-five @entity978 @entity1 (37%) received HDCT. Most @entity1 with @entity1893 had progressive disease under salvage treatment, with only six @entity1 (10%) receiving HDCT. Of those, only two @entity1 were alive and in continuous complete remission 3 and 12 months after HDCT. No @entity1 with @entity1893 survived longer than 26 months after first diagnosis. @entity3012 after 5 years was 19% for all @entity978 @entity1 ; 53% for @entity978 @entity1 receiving HDCT, and 0% for @entity1 who did not receive HDCT. In @entity978 @entity1 , multivariate regression analysis identified chemosensitive disease on salvage treatment (P =.0001) and HDCT (P =.031) as significant prognostic factors for freedom from treatment failure. Significant prognostic factors for @entity3012 are chemosensitive disease (P =.0005), HDCT (P =.039), and B symptoms at the time of progress (P =.046). CONCLUSION: There are striking differences in the prognosis of @entity1 with progressive @entity978 and aggressive @entity1893 . The prognosis of progressive @entity1893 @entity1 is dismal. Most @entity1 have rapidly progressive disease after salvage treatment and are, therefore, excluded from HDCT programs. In contrast, progressive @entity978 @entity1 can achieve long-term survival after HDCT.

Treatment of primary progressive XXXX : is there a chance for cure?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity706 :: ('MESH:D008223', 'Disease') :: ['progressive lymphoma'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['Actuarial OS', 'OS'] @entity74 :: ('MESH:D030342', 'Disease') :: ['Primary progressive disease'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HD', "Hodgkin's disease"]
@entity1893 :: (MESH:D008228,Disease) :: ['Hodgkin's and aggressive non-Hodgkin's lymphoma']
